The recombinant subunit VLP vaccine not only has the potential to rapidly deliver an effective and safe prophylaxis for COVID-19, but also an economic, scalable, high-yield and large-scale production capability, according to the company. These are key assets for addressing the current pandemic and predicted global vaccine supply issues. The vaccine has been engineered to enhance immune responsiveness in elderly people, a high-risk group for COVID-19.
"I am pleased to work with the AGC Biologics team again on such an important vaccine development project," said Martin Bachmann, founder and inventor, Saiba AG. "AGC Biologics' expertise and competence in VLP manufacturing is an important enabler for our rapid development plans, which include commencement of clinical trials and contribution to national vaccine supply in Q4 2020. We are happy to build upon our foundational long-term relationship as we share the same values to serve patients through science."
Mark Womack, CBO, AGC Biologics, said, "Partnering with Saiba AG to manufacture this vaccine gives us an opportunity to make a very positive difference. During these unprecedented times, it is our responsibility to provide our customers with the lifesaving products they need. We're very proud to partner with Saiba AG on such an important project."